ZFIN ID: ZDB-FISH-150901-521
Fish name: tp53zdf1/zdf1; nn1004Tg
Genotype: tp53zdf1/zdf1; nn1004Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by tp53zdf1/zdf1; nn1004Tg
Human Disease Conditions Citations
hepatocellular carcinoma control Lin et al., 2019
GENE EXPRESSION
Gene expression in tp53zdf1/zdf1; nn1004Tg
Reporter gene expression
Expressed Gene Structure Conditions Figures
EGFP standard conditions Fig. S7 with image from Lu et al., 2013
PHENOTYPE
Phenotype in tp53zdf1/zdf1; nn1004Tg
Phenotype Conditions Figures
hepatocyte fatty, abnormal standard conditions Fig. 6 with image from Lu et al., 2013
hepatocyte hyperplastic, abnormal standard conditions Fig. 6 with imageFig. 7 with image from Lu et al., 2013
hepatocyte mitotic cell cycle increased frequency, abnormal standard conditions Fig. 6 with imageFig. 7 with imageFig. 8 with image from Lu et al., 2013
hepatocyte nucleolus prominent, abnormal standard conditions Fig. 6 with imageFig. 7 with imageFig. 8 with image from Lu et al., 2013
hepatocyte nucleus increased size, abnormal standard conditions Fig. 6 with imageFig. 7 with imageFig. 8 with image from Lu et al., 2013
liver cdk2 expression amount, ameliorated chemical treatment by injection: sorafenib Fig. 5 with image from Lin et al., 2019
liver cdk1 expression amount, ameliorated chemical treatment by injection: sorafenib Fig. 5 with image from Lin et al., 2019
liver cdk1 expression amount, ameliorated chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Fig. 5 with image from Lin et al., 2019
liver ccne1 expression amount, ameliorated chemical treatment by injection: sorafenib Fig. 5 with image from Lin et al., 2019
liver ccne1 expression amount, ameliorated chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Fig. 5 with image from Lin et al., 2019
liver cdk2 expression amount, ameliorated chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Fig. 5 with image from Lin et al., 2019
liver dysplastic, abnormal control Fig. 5 with image from Lin et al., 2019
liver hyperplastic, abnormal control Fig. 5 with image from Lin et al., 2019
liver ccne1 expression increased amount, abnormal control Fig. 5 with image from Lin et al., 2019
liver cdk2 expression increased amount, abnormal control Fig. 5 with image from Lin et al., 2019
liver cdk1 expression increased amount, abnormal control Fig. 5 with image from Lin et al., 2019
liver structure, ameliorated chemical treatment by injection: sorafenib Fig. 5 with image from Lin et al., 2019
liver structure, ameliorated chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Fig. 5 with image from Lin et al., 2019
liver hepatic tumor increased occurrence, abnormal standard conditions Fig. 6 with imageFig. 7 with imageFig. 8 with image from Lu et al., 2013
liver hepatocellular carcinoma amount, ameliorated chemical treatment by injection: sorafenib Fig. 5 with image from Lin et al., 2019
liver hepatocellular carcinoma amount, ameliorated chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Fig. 5 with image from Lin et al., 2019
liver hepatocellular carcinoma increased amount, abnormal control Fig. 5 with image from Lin et al., 2019
liver lipid amount, ameliorated chemical treatment by injection: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor Fig. 5 with image from Lin et al., 2019
liver lipid amount, ameliorated chemical treatment by injection: sorafenib Fig. 5 with image from Lin et al., 2019
liver lipid increased amount, abnormal control Fig. 5 with image from Lin et al., 2019
liver spindle cell sarcoma increased occurrence, abnormal standard conditions Fig. 7 with imageFig. 8 with image from Lu et al., 2013

CITATIONS  (4)